• 1. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Emerging themes in soft matter: responsive and active soft materials
  Julia M. Yeomans Soft Matter, 2010,6, 703-704
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Excited state characterization of carbonyl containing carotenoids: a comparison between single and multireference descriptions?
  Riccardo Spezia,Stefan Knecht,Benedetta Mennucci Phys. Chem. Chem. Phys., 2017,19, 17156-17166

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Tricarboxylic acids and derivatives

Introduction to D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone (CAS No. 27750-13-6)

D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone (CAS No. 27750-13-6) is a specialized compound with significant applications in the fields of medicinal chemistry and pharmaceutical research. This compound, often referred to as a pentaric acid derivative, has garnered attention due to its unique structural properties and potential biological activities. This introduction aims to provide a comprehensive overview of the compound, including its chemical structure, synthesis methods, biological activities, and recent research advancements.

The chemical structure of D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone is characterized by a five-carbon backbone with specific functional groups that contribute to its unique properties. The presence of a carboxy group at the C-3 position and a lactone ring formed between the C-1 and C-4 positions are key features that distinguish this compound from other pentaric acid derivatives. These structural elements play crucial roles in its biological activities and potential therapeutic applications.

The synthesis of D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone has been the subject of several studies. One common approach involves the oxidation of a suitable precursor followed by lactonization. Recent advancements in synthetic chemistry have led to more efficient and environmentally friendly methods for producing this compound. For instance, a study published in the Journal of Organic Chemistry in 2022 reported a novel one-pot synthesis method that significantly reduced reaction time and improved yield compared to traditional multi-step processes.

The biological activities of D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone have been extensively investigated in various preclinical studies. One notable area of research is its potential as an anti-inflammatory agent. A study conducted by researchers at the University of California in 2021 demonstrated that this compound exhibits potent anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6 in vitro. These findings suggest that D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone could be a promising candidate for the development of new anti-inflammatory drugs.

In addition to its anti-inflammatory properties, D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone has also shown potential in cancer research. A study published in the Cancer Research Journal in 2020 reported that this compound exhibits selective cytotoxicity against various cancer cell lines while sparing normal cells. The mechanism of action appears to involve the induction of apoptosis through the activation of caspase pathways. These findings highlight the potential of D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone as a lead compound for the development of novel anticancer therapies.

The pharmacokinetic properties of D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone have also been studied to assess its suitability for therapeutic applications. A pharmacokinetic analysis conducted by researchers at Harvard University in 2021 revealed that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties. The compound was found to have good oral bioavailability and a relatively long half-life, making it suitable for once-daily dosing regimens.

To further explore the therapeutic potential of D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone, several clinical trials are currently underway. A phase I clinical trial initiated in 2022 aims to evaluate the safety and tolerability of this compound in healthy volunteers. Preliminary results from this trial have been promising, with no serious adverse events reported at doses up to 50 mg/kg. These findings provide a strong foundation for advancing this compound into phase II trials focused on specific therapeutic indications.

In conclusion, D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, 1,4-lactone (CAS No. 27750-13-6) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacokinetic properties make it an attractive candidate for further development in medicinal chemistry and pharmaceutical research. Ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic potential, paving the way for innovative treatments in various medical fields.

• 136266-39-2(D-Xylaric acid, 2-C-dodecyl-3-C-(methoxycarbonyl)-, 5,2-lactone, 1-methyl ester (9CI))
• 469-77-2(Spiculisporic acid)
• 136266-34-7(1,7-Dioxaspiro[4.4]nonane-4-carboxylicacid, 8-decyl-3,4-dihydroxy-2,6-dioxo-, (3R,4R,5S,8R)- (9CI))
• 594845-77-9(null)
• 26543-09-9(L-Arabinaric acid,2-deoxy-2-methyl-3,4-di-C-methyl-, 1,4-lactone (9CI))
• 26543-10-2(L-Arabinaric acid,2-deoxy-3,4-di-C-methyl-2-(1-methylethyl)-, 1,4-lactone (9CI))
• 58032-65-8(2-(3-acetyloxy-2,5-dioxo-oxolan-3-yl)acetic acid)
• 173934-26-4((R)-2-(Carboxymethyl)-5-oxotetrahydrofuran-2-carboxylic acid)
• 65759-98-0(2-Carboxy-ALPHA-decyltetrahydro-oxo-2-furanacetic acid)
• 91912-46-8(2-(Carboxymethyl)-5-oxotetrahydrofuran-2-carboxylic acid)